Renovaro Biosciences Inc (RENB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Renovaro Biosciences Inc (RENB) has a cash flow conversion efficiency ratio of 0.085x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.81 Million) by net assets ($-21.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Renovaro Biosciences Inc for the company's overall valuation and market capitalisation.
Renovaro Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Renovaro Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Renovaro Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Renovaro Biosciences Inc ranked by their cash flow conversion efficiency. Explore Renovaro Biosciences Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unlimited Travel Group UTG AB (publ)
ST:UTG
|
1.638x |
|
Softing AG
XETRA:SYT
|
0.015x |
|
Gediz Ambalaj Sanayi ve Ticaret AS
IS:GEDZA
|
0.012x |
|
Odessa Minerals Ltd
AU:ODE
|
-0.066x |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
0.030x |
|
Aware Inc
NASDAQ:AWRE
|
-0.134x |
|
CompuLab Ltd
TA:CLAB
|
0.080x |
|
Metal Energy Corp
V:MERG
|
0.042x |
Annual Cash Flow Conversion Efficiency for Renovaro Biosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Renovaro Biosciences Inc from 2012 to 2025. View latest Renovaro Biosciences Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $131.98 Million | $-10.97 Million | -0.083x | 0.00% |
| 2024-06-30 | $131.98 Million | $-10.97 Million | -0.083x | +67.17% |
| 2023-06-30 | $46.50 Million | $-11.77 Million | -0.253x | -16.88% |
| 2022-06-30 | $72.62 Million | $-15.73 Million | -0.217x | -83.59% |
| 2021-06-30 | $174.66 Million | $-20.61 Million | -0.118x | -87.59% |
| 2020-06-30 | $166.27 Million | $-10.46 Million | -0.063x | -27.99% |
| 2019-06-30 | $173.10 Million | $-8.51 Million | -0.049x | -79.83% |
| 2018-06-30 | $158.74 Million | $-4.34 Million | -0.027x | +96.44% |
| 2017-06-30 | $1.53 Million | $-1.18 Million | -0.768x | -133.26% |
| 2016-06-30 | $-637.40K | $-1.47 Million | 2.310x | +495.42% |
| 2015-06-30 | $3.48 Million | $-2.03 Million | -0.584x | -143.88% |
| 2014-06-30 | $-1.60 Million | $-2.13 Million | 1.331x | +126.81% |
| 2013-06-30 | $-51.27K | $-30.09K | 0.587x | -67.81% |
| 2012-06-30 | $-13.68K | $-24.95K | 1.823x | -- |
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more